Stockscreener 앱 받기
98.77
0.30%
0.15
시간 외 거래:
98.90
0.13
+0.13%
전일 마감가:
$98.62
열려 있는:
$98.84
하루 거래량:
500.17K
Relative Volume:
0.51
시가총액:
$6.03B
수익:
$521.31M
순이익/손실:
$-23.36M
주가수익비율:
-206.59
EPS:
-0.4781
순현금흐름:
$54.87M
1주 성능:
+3.41%
1개월 성능:
+8.12%
6개월 성능:
+35.26%
1년 성능:
+124.81%
1일 변동 폭
$95.62
$99.99
1주일 범위
$95.62
$101.96
52주 변동 폭
$43.30
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
98.96 | 6.01B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
US604749AC5 Bond Analysis — Key Metrics - TradingView
US604749AC5 Bond Price and Chart — FWB:US604749AC5 - TradingView
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM) - Yahoo Finance
Behavioral Patterns of MIRM and Institutional Flows - Stock Traders Daily
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum Pharmaceuticals Set to Present Key Data at International L - GuruFocus
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 - Business Wire
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
MIRM: Clinical and commercial catalysts drive growth, with major pipeline and BD milestones ahead - TradingView
Mirum Pharma: A rare disease growth story to watch - MSN
Mirum Pharma: A Rare Disease Growth Story to Watch - sharewise.com
Wolfe Research initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock By Investing.com - Investing.com Nigeria
This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research initiates Mirum stock with outperform rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock - Investing.com UK
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes - Stock Titan
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals prices $600M senior notes - MSN
2,000-share sale via option exercise — MIRM (NASDAQ: MIRM) Form 144 - Stock Titan
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised - MSN
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last? - MSN
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering - Latham & Watkins LLP
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(MIRM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal - AD HOC NEWS
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD - Investing.com
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering - Moomoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes - BioSpace
Mirum plans $600 million convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering - TradingView
Mirum raises $600M in 0% convertible notes, starts 2029 debt swap - Stock Titan
Mirum pharmaceuticals announces proposed convertible senior notes offering - marketscreener.com
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - TradingView
Mirum Pharmaceuticals shares fall 2% after announcing $600 million bond offering - Investing.com Canada
Mirum plans $600 million convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mirum Pharmaceuticals Inc 주식 (MIRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ramasastry Saira | Director |
May 15 '26 |
Sale |
109.47 |
2,000 |
218,940 |
0 |
1.49%
0.12%
자본화:
|
볼륨(24시간):